The Effect of Disease-Modifying Therapies on Lung Function and Respiratory Muscle Strength in Spinal Muscular Atrophy: Systematic Review and Meta-Analysis
Respiratory Care · 2025
DOI: 10.4187/respcare.12378 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift Respiratory Care, 2025. Verfasst von Kim Kant-Smits und 6 weiteren Autor:innen. Beteiligte Einrichtung: Ms. Kant-Smits and Drs. Bartels and Hulzebos are affiliated with Child Development and Exercise Center, Wilhelmina Children's Hospital, University Me…. Hauptthemen laut MEDLINE: Muscle Strength, Respiratory Muscles, Muscular Atrophy, Spinal, Lung. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 41 Literaturangaben.
Abstract (Originalsprache)
Background
Spinal muscular atrophy (SMA) is often complicated by respiratory problems. The disease-modifying therapies (DMTs) (nusinersen, onasemnogene abeparvovec, and risdiplam) have improved survival, motor function, and functional muscle strength in patients with SMA, but their effects on lung function and respiratory muscle strength need further clarification. Therefore, we performed a systematic review of studies that documented the effects of DMTs on lung function and respiratory muscle strength in patients with SMA types I, II, III, and IV.
Methods
We searched the electronic databases PubMed/MEDLINE, CINAHL, Embase, and Web of Science up to December 2023. We included pre-post studies that determined the effect of DMTs for SMA on lung function or respiratory muscle strength in patients with SMA. Where possible, we performed a meta-analysis using a random-effects model with generic inverse variance weighing.
Results
We included 19 studies of 376 identified records (16 longitudinal cohort studies and 3 case series) with 384 participants. Seventeen studies investigated the effect of nusinersen, and two studies investigated the effect of risdiplam. Seventeen studies had a moderate and two had a high risk of bias. Most of these studies did not report statistically significant improvement in lung function or respiratory muscle strength after treatment with nusinersen or risdiplam. A meta-analysis of 13 studies showed no statistically significant improvement in FVC after 2, 6, 10, and > 12 months of treatment with nusinersen.
Conclusions
The findings of this review indicate that there is moderate evidence that nusinersen does not improve FVC, FEV1, peak expiratory flow, or maximum inspiratory pressure in subjects with SMA types I, II, III, or IV. There was no statistically significant decline in lung function and respiratory muscle strength after treatment. This may suggest that nusinersen may have stabilized lung function and respiratory muscle strength.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Ms. Kant-Smits and Drs. Bartels and Hulzebos are affiliated with Child Development and Exercise Center, Wilhelmina Children's Hospital, University Medical Center Utrecht, the Netherlands.
- Ms. van der Heiden is affiliated with Fysiocompany Kortbeek, Vught, the Netherlands.
- Dr. Veldhoen is affiliated with Department of Pediatric Intensive Care, University Medical Centre Utrecht, Utrecht, the Netherlands.
- Dr. van der Ent is affiliated with Department of Pediatric Respiratory Medicine, Wilhelmina Children's Hospital, University Medical Center Utrecht, Utrecht, the Netherlands.
- Dr. van der Pol is affiliated with Department of Neurology and Neurosurgery, UMC Utrecht Brain Center, University Medical Center Utrecht, Utrecht, the Netherlands.
Zitieren
APA
Kant-Smits, K., Bartels, B., van der Heiden, L., Veldhoen, E. S., van der Ent, K., van der Pol, W. L., & Hulzebos, E. H. J. (2025). The Effect of Disease-Modifying Therapies on Lung Function and Respiratory Muscle Strength in Spinal Muscular Atrophy: Systematic Review and Meta-Analysis. Respiratory Care. https://doi.org/10.4187/respcare.12378
Vancouver
Kant-Smits K, Bartels B, van der Heiden L, Veldhoen ES, van der Ent K, van der Pol WL, et al. The Effect of Disease-Modifying Therapies on Lung Function and Respiratory Muscle Strength in Spinal Muscular Atrophy: Systematic Review and Meta-Analysis. Respiratory Care. 2025. doi:10.4187/respcare.12378
BibTeX
@article{KantSmits2025,
author = {Kant-Smits, Kim and Bartels, Bart and van der Heiden, Laura and Veldhoen, Esther S and van der Ent, Kors and van der Pol, W Ludo and Hulzebos, Erik H J},
title = {The Effect of Disease-Modifying Therapies on Lung Function and Respiratory Muscle Strength in Spinal Muscular Atrophy: Systematic Review and Meta-Analysis},
journal = {Respiratory Care},
year = {2025},
doi = {10.4187/respcare.12378}
}
EUVIMED